R.M. SHAKIROVA, G.M. KAMALOV

 Kazan State Mеdical University, Kazan

 Contact details:

Shakirova R.M. — PhD (Medicine), Assistant Lecturer of the Department of Сardiology

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7-917-297-76-94, e-mail: reginash77@mail.ru

Oncologic disease and concomitant treatment are among the main triggers for Takotsubo syndrome. A clinical case of Takotsubo syndrome in cancer is presented. Thyroid carcinoma and thyroidectomy contributed to the development of Takotsubo syndrome. The clinical manifestations are similar to those of acute myocardial infarction. Coronarography is important in the differential diagnosis. Patients with cancer are at high risk of developing Takotsubo syndrome and should be under close clinical observation. A patient with Takotsubo syndrome should be hospitalized in an intensive care or cardiac intensive care unit. The management and treatment of patients with this pathology should be discussed by a multidisciplinary team.

Key words: Takotsubo syndrome, stress-induced cardiomyopathy, cancer, thyroidectomy.

REFERENCES

1. 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur. Heart J, 2023, vol. 44 (37), pp. 3503–3626. DOI: 10.1093/eurheartj/ehad194
2. Giza D.E., Lopez-Mattei J., Vejpongsa P. et al. Stress-induced cardiomyopathy in cancer patients. Am. J. Cardiol, 2017, vol. 120 (12), pp. 2284–2288. DOI: 10.1016/j.amjcard.2017.09.009
3. Cammann V.L., Sarcon A., Ding K.J. et al. Clinical features and outcomes of patients with malignancy and Takotsubo syndrome: observations from the International Takotsubo Registry. J. Am. Heart Assoc, 2019, vol. 8 (15), e010881. DOI: 10.1161/JAHA.118.010881
4. Macedo et al. Takotsubo cardiomyopathy in patients with cancer. ABC Heart Fail Cardiomyop, 2022, vol. 2 (4), pp. 374–380. DOI: 10.36660/abchf.20220083
5. Shams Y., Falhammar H. Pheochromocytoma- and paraganglioma-triggered Takotsubo syndrome. Endocrine, 2019, vol. 65, pp. 483–493.
6. Desai A., Noor A., Joshi S., Kim A.S. Takotsubo cardiomyopathy in cancer patients. Cardio-oncology, 2019, vol. 5, p. 7. DOI: 10.1186/s40959-019-0042-9
7. Keramida K., Farmakis D., Filippatos G. Cancer and Takotsubo syndrome: from rarity to clinical practice. ESC Heart Failure, 2021, vol. 8 (6), pp. 4365–4369. DOI: 10.1002/ehf2.13741
8. Desai R., Desai A., Abbas S.A. et al. National prevalence, trends and outcomes of Takotsubo syndrome in hospitalizations with prior history of mediastinal / intrathoracic cancer and radiation therapy. Int. J. Cardiol, 2020, vol. 309, pp. 14–18. DOI: 10.1016/j.ijcard.2020.02.036
9. Bilal M., Raza M., Molloy M. et al. Chemotherapy induced Takotsubo cardiomyopathy. J. Hosp. Med. Manage, 2021, vol. 7 (8), p. 286.
10. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the International cardio-oncology society (IC-OS). Eur. Heart J, 2022, vol. 43 (41), pp. 4229–4361. DOI: 10.1093/eurheartj/ehac244
11. Osawa T., Tajiri K., Ieda M., Ishizu T. Clinical outcomes of Takotsubo syndrome in patients with cancer: a systematic review and meta-analysis. Front Cardiovasc. Med., 2023, vol. 10, 1244808. DOI: 10.3389/fcvm.2023.1244808.
12. Carbone A., Bottino R., Russo V. et al. Takotsubo cardiomyopathy as epiphenomenon of cardiotoxicity in patients with cancer: a meta-summary of case reports. J. Cardiovasc. Pharmacol, 2021, vol. 78 (1), pp. 20–29. DOI: 10.1097/FJC.0000000000001026.
13. Coen M., Rigamonti F., Roth A., Koessler T. Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature. BMC Cancer, 2017, vol. 17 (1), p. 394. DOI: 10.1186/s12885-017-3384-4
14. Keramida K., Parissis J.T., Chioncel O., Farmakis D. Cardiogenic shock in cancer. Heart Fail. Rev, 2019, vol. 24 (6), pp. 997–1004. DOI: 10.1007/s10741-019-09819-9